Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2007. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, and connected persons, specifically regarding changes in their interests in the company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider trading activity and does not contain financial performance data.
Material Changes and Transactions
The filing details specific transactions executed on February 27, 2007, primarily to meet tax liabilities following the vesting of Performance Share Plan awards:
- Ordinary Shares Sales: Sold at GBP 14.37 per share.
- Mr J S Heslop: 1,025 shares
- Dr M M Slaoui: 740 shares
- Mr J Clarke: 2,870 shares
- Mr D Learmouth: 615 shares
- ADS Sales: Sold at $56.45 per ADS.
- Mr W Louv: 325 ADSs
- Grants to Connected Persons: On February 26, 2007, Dr M M Slaoui's spouse received awards including 1,570 ADSs under the Performance Share Plan, 3,570 options under the Share Option Plan (subscription price $58.00 per ADS), and 890 units under the Share Value Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to regulatory notification of share transactions.
Key Facts for Investor Verification
- Verify the total volume of insider sales (Ordinary Shares and ADSs) executed on February 27, 2007.
- Confirm the transaction prices: GBP 14.37 per Ordinary Share and $56.45 per ADS.
- Note that sales were executed specifically to meet tax liabilities arising from vesting awards.
- Review the specific grants made to Dr M M Slaoui's spouse, including the $58.00 subscription price for share options.